In the preclinical stage of AD‐related cognitive impairment, patients lack clinical symptoms but exhibit positive biomarkers (Aβ‐PET+, CSF: Aβ42/40 ratio; p‐tau181/ Aβ42; t‐tau/ Aβ42, Blood: p‐tau217; p‐tau217/np‐tau217).288. This evidence concerns the gene MAPT and Alzheimer disease.